INTI
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Inhibitor Therapeutics, Inc. (INTI) is rated D (1.3/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Momentum (C); its weakest is Value (F). The rating has held at D for 173 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-07-29 | F (0.0) | C- (2.0) | D- (0.9) | C (2.2) | D+ (1.5) | D (1.3) |
| 2023-06-30 | F (0.0) | C- (2.1) | D- (1.0) | C (2.3) | D (1.5) | D (1.4) |
| 2023-03-31 | F (0.0) | C+ (2.5) | D- (1.0) | C (2.3) | D (1.5) | D (1.4) |